Surprising plant molecule could drive a new wave of drugs and biotechnology

A new scientific review argues that papain, the signature enzyme from papaya, could power a new wave of medicines and biotech tools. The central claim is simple, one familiar fruit hosts an enzyme with reach across clinics and factories.

The review authors sifted studies on chemistry, safety, and real world uses, then call for smarter drug development around this natural protein. Their review weighs lab data and human findings to size up what papain can and cannot do.

Why papain matters now

The work was led by Benjamin Ayodipupo Babalola, a biochemistry researcher, at Purdue University. His research focuses on papain and related plant enzymes with practical medical uses.

Papain is not a novelty ingredient. It shows up in meat tenderizers, helps clarify some beverages, and has been explored in wound gels.

Interest is rising because supply is steady in tropical agriculture and because enzyme based therapeutics can be tuned with modern formulation methods. That mix puts papain on the short list for low cost bioprocessing and drug candidates.

“C. papaya emerged as a reservoir of pharmacological activities,” wrote Babalola, making a broad point about the plant itself. 

What the papain enzyme does

Papain is a cysteine protease, a protein cutting enzyme that uses a sulfur bearing amino acid. That chemistry lets it break peptide bonds with precision in warm, watery conditions.

Its two-domain structure was mapped at 1.65 A resolution, revealing an active groove that fits many protein targets. That physical layout explains why papain works in food and biomedical settings.

Activity peaks in mildly acidic conditions and in heat common to kitchens or body care products. In practical terms, papain remains active around 122 to 138 degrees Fahrenheit, a range useful for manufacturing and some topical applications.

Papain dissolves in water and stays reasonably stable with the right helpers, including certain amino acids and chelators. This stability matters for shelf life and for dosing that does not swing wildly over time.

From kitchen uses to clinical risks

Plants make enzymes for their own defense. A classic study showed that latex proteases like papain help papaya leaves fend off caterpillars that try to feed on them.

People have long borrowed that chemistry in the kitchen and the lab. The same protein cutting power that softens steak also can clean protein films from contact lenses or help remove dead tissue in wounds.

Caution is required with topical drug products that contain papain. The FDA documented 37 adverse events, including life threatening reactions, before ordering companies to stop marketing unapproved topical papain in 2008.

A severe reaction called anaphylaxis, a sudden and dangerous whole body allergy response, was among the risks regulators weighed. That history does not end papain’s medical future, but it sets the bar for safety testing and product approval.

Signals from real patients

Evidence in infectious disease has drawn attention, especially where care options are limited. In an open label randomized trial with 228 dengue patients, papaya leaf juice increased platelet counts over 48 hours compared with standard care.

Doctors watch platelets closely in thrombocytopenia, a condition of low platelets that can raise bleeding risk. Early clinical signals are encouraging, yet they do not replace supportive care or vector control in dengue.

The trial design was simple and short, which leaves open questions about durability, dosing, and safety in diverse patients. Follow up studies with blinded designs and longer monitoring would clarify how to use papaya extracts responsibly.

The bottom line for now is cautious optimism. Signals from small trials can guide larger, stricter evaluations, not clinical shortcuts.

Separating papain promise from hype

Papain’s biochemistry gives it a real toolkit. It can be formulated with stabilizers, activated by certain ions, and paired with substrates in controlled ways.

That said, not all applications are equally plausible. Claims that papain alone can treat complex cancers or chronic diseases ignore the need for targeted delivery and careful immune monitoring.

Quality control is another sticking point. Plant based extracts can vary by cultivar, soil, and processing, so standardized production is essential for consistent dosing.

Regulatory history should also inform strategy. A clear path that moves from lab assays to well designed trials, followed by approval for specific indications, protects patients and builds trust.

Next steps in drug development

Enzyme engineering can sharpen papain’s performance. Swapping surface residues, optimizing pH windows, or attaching delivery tags could improve tissue access without blunt side effects.

Formulation science matters just as much as mutations. Stabilizers that keep activity steady in real world temperatures and packaging can make or break an over the counter digestive aid or a prescription therapy.

Combination approaches look promising. Pairing papain with antibiotics or antivirals might improve penetration into biofilms or viscous secretions where drugs struggle to reach their targets.

Finally, cost and access should stay in view. A successful papain product that is stable at room temperature and easy to manufacture could help patients far from advanced hospitals.

The study is published in Arabian Journal of Chemistry.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–